Following this, patients with moderate COVID‐19 have progressive reduction in Th1 cell IFN‐γ type‐1 antiviral macrophage activation and Th17 cell IL‐17 and IL‐22 type‐3 antifungal‐like neutrophil mediated responses. Here, IL17A is linked to COVID-19.